Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2754361 | Clinical Lymphoma Myeloma and Leukemia | 2015 | 11 Pages |
Abstract
The goal of this review is to provide historical, recent preclinical, and current clinical summaries of efforts to understand the CD38 molecule and to develop monoclonal antibodies that target it. We focus particularly on efforts involving multiple myeloma, a malignancy of terminally differentiated B cells that remains incurable despite many advances. An era of anti-CD38 monoclonal antibody therapy for myeloma is approaching, one that, we hope, will enable patients to live longer and better lives.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Sandy W. Wong, Raymond L. Comenzo,